Exciting developments are transforming the treatment landscape for chronic lymphocytic
leukaemia, with new therapies and combinations set to redefine care in first-line and relapsed/
refractory settings.
Exciting developments are transforming the treatment landscape for chronic lymphocytic leukaemia, with new therapies and combinations set to redefine care in first-line and relapsed/refractory settings.
Don’t miss this exclusive opportunity to join Associate Professor Mazyar Shadman and a panel of UK experts for an engaging in-person meeting series around the country. Be part of the discussion as they unpack the latest data and share practical insights on how these advances are shaping real-world clinical practice.
Please direct queries to: https://thelimbic.com/contact-us/
